- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Zenas BioPharma, Inc. GAAP EPS of -$5.02 | 2 | Seeking Alpha | ||
| 12.11. | Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 87 | GlobeNewswire (Europe) | -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-... ► Artikel lesen | |
| 12.11. | Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | 118 | GlobeNewswire (Europe) | -INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma... ► Artikel lesen | |
| 07.11. | Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences | 210 | GlobeNewswire (Europe) | WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the... ► Artikel lesen | |
| 08.10. | Zenas started at buy by four banks on lead drug potential | 2 | Seeking Alpha | ||
| 08.10. | Morgan Stanley bullisch für Zenas Biopharma-Aktie aufgrund zunehmender Dynamik bei obexelimab-Studien | 8 | Investing.com Deutsch | ||
| 08.10. | Citi sieht Aufwärtspotenzial für Zenas Biopharma-Aktie aufgrund von Fortschritten bei Obexelimab in wichtigen Studien | 3 | Investing.com Deutsch | ||
| 08.10. | Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials | 3 | Investing.com | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.10. | Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum | 4 | Investing.com | ||
| 08.10. | Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials | 1 | Investing.com | ||
| 08.10. | Guggenheim setzt auf Zenas-Aktie aufgrund vielversprechender Aussichten für Hauptmedikament Obexelimab | 2 | Investing.com Deutsch | ||
| 08.10. | Jefferies zeigt sich bullisch für Zenas-Aktie aufgrund von Fortschritten bei Obexelimab in Autoimmun-Studien | 2 | Investing.com Deutsch | ||
| 08.10. | Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab | 2 | Investing.com | ||
| 21.09. | Zenas BioPharma CEO acquires $360k worth of company shares | 1 | Investing.com | ||
| 19.09. | Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | 262 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and... ► Artikel lesen | |
| 18.09. | Zenas BioPharma director acquires $999k in company stock | 3 | Investing.com | ||
| 17.09. | IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx | 2 | The Armchair Trader | ||
| 17.09. | Zenas BioPharma director buys $7.48m in company stock | 1 | Investing.com | ||
| 17.09. | Zenas BioPharma director Jason Raleigh acquires $15 million in company stock | 4 | Investing.com | ||
| 17.09. | Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 273,45 | +0,09 % | Dividendenbekanntmachungen (18.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0569 EUR ALGOMA CENTRAL CORPORATION CA0156441077 0,19 CAD 0,128 EUR ALLISON TRANSMISSION... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 707,80 | +0,37 % | Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria | PARIS (dpa-AFX) - French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration has accepted for review the resubmission... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 59,10 | +1,62 % | BioMarin: Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced positive and consistent results from multiple real-world evidence studies of VOXZOGO (vosoritide) in children with achondroplasia.... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 17,540 | -1,27 % | Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS | ||
| SWEDISH ORPHAN BIOVITRUM | 24,860 | -0,80 % | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the... ► Artikel lesen | |
| INSMED | 68,00 | -1,45 % | Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday | ||
| SCHOLAR ROCK | 26,400 | 0,00 % | Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... ► Artikel lesen | |
| PROQR THERAPEUTICS | 3,408 | -2,29 % | ProQR Therapeutics Aktie: Weg in die Zukunft geebnet! | ProQR Therapeutics, ein niederländisches Biotechnologieunternehmen, zeigt sich trotz herausfordernder Marktbedingungen widerstandsfähig. Die Aktie verzeichnete am 2. November 2024 einen leichten Rückgang... ► Artikel lesen | |
| THERATECHNOLOGIES | 1,060 | 0,00 % | Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance | MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 51,00 | -4,67 % | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 21,180 | 0,00 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $410 - $420 million -- Life... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,648 | 0,00 % | Ensysce Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary | ||
| VENTYX BIOSCIENCES | 1,725 | 0,00 % | Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts | ||
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 12,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.
